New drug duo takes on tough lymphoma

NCT ID NCT07578077

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new drug, golcadomide, combined with rituximab for people with mantle cell lymphoma that has come back or stopped responding to treatment. The study aims to find the safest dose and see if the combination can shrink tumors. About 58 adults will take part, and researchers will monitor side effects and how long any benefits last.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

golcadomide and rituximab

What this could lead to

If successful, this could offer a new treatment option for patients with mantle cell lymphoma that has returned or stopped responding to therapy.

What could go wrong

This is an early-phase trial (phase 1/2) with only 58 participants, so results may not apply broadly. Side effects and lack of effectiveness are possible risks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT MANTLE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • City of Hope Medical Center

    Duarte, California, 91010, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact